🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Stryker Corporation (SYK)

NYSE
Currency in USD
375.06
-1.10(-0.29%)
Closed
Pre Market
377.00+1.94(+0.52%)
SYK Scorecard
Full Analysis
Has raised its dividend for 15 consecutive years
Fair Value
Day's Range
374.62378.09
52 wk Range
285.79398.20
Key Statistics
Edit
Prev. Close
375.06
Open
377
Day's Range
374.62-378.09
52 wk Range
285.79-398.2
Volume
846.13K
Average Volume (3m)
1.16M
1-Year Change
25.64%
Book Value / Share
52.87
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SYK Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
403.67
Upside
+7.63%
Members' Sentiments
Bearish
Bullish
ProTips
24 analysts have revised their earnings downwards for the upcoming period
Show more

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Stryker Corporation SWOT Analysis


Stellar Performance
Stryker's Q3 2024 results showcase exceptional organic growth of 11.5%, surpassing expectations and driving positive analyst revisions
Innovation Leade
Explore Stryker's cutting-edge product pipeline, including robotic surgery platforms and minimally invasive technologies driving market leadership
Global Expansion
Delve into Stryker's international growth strategy, with strong performance in Europe, emerging markets, and Asia-Pacific regions
Analyst Outlook
Analyst price targets range from $360 to $418, reflecting confidence in Stryker's growth potential and market positioning
Read full SWOT analysis
SYK Full Pro Research
Institutional-Grade Stock Analysis
Understand how SYK earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Stryker Corporation Earnings Call Summary for Q4/2024

  • Stryker reports 11.5% organic sales growth in Q3, with adjusted EPS of $2.87, up 16.7% year-over-year
  • Full-year 2024 guidance narrowed to 9.5%-10% organic sales growth and adjusted EPS of $12-$12.10
  • Strategic acquisitions completed, including Care.ai and NICO Corporation, to enhance healthcare IT and surgical offerings
  • Record Mako installations achieved; orthopedic business shows above-market growth despite flat revenue from rental agreements
  • Company aims for 200 basis point margin expansion by 2025, driven by innovation and strong procedural volumes
Last Updated: 30/10/2024, 20:14
Read Full Transcript

Compare SYK to Peers and Sector

Metrics to compare
SYK
Peers
Sector
Relationship
P/E Ratio
39.8x−7.9x−0.6x
PEG Ratio
1.040.180.00
Price/Book
7.1x4.1x2.6x
Price / LTM Sales
6.5x2.8x3.2x
Upside (Analyst Target)
7.7%58.7%45.4%
Fair Value Upside
Unlock5.8%7.7%Unlock

Analysts' Recommendations

22 Buy
9 Hold
1 Sell
Ratings:
28 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 402.49

(+7.31% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 9.43
Dividend Yield
0.85%
Industry Median 0.73%
Annualised payout
3.2000
Paid quarterly
5-Years Growth
+9.00%
Growth Streak

People Also Watch

366.85
SHW
-1.37%
42.05
ENB
-0.68%
211.59
CTAS
+0.29%
682.57
PH
-0.56%
298.75
ADP
-0.67%

FAQ

What Is the Stryker (SYK) Stock Price Today?

The Stryker stock price today is 375.06

What Stock Exchange Does Stryker Trade On?

Stryker is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Stryker?

The stock symbol for Stryker is "SYK."

Does Stryker Pay Dividends? What’s The Current Dividend Yield?

The Stryker dividend yield is 0.90%.

What Is the Stryker Market Cap?

As of today, Stryker market cap is 142.98B.

What is Stryker Earnings Per Share?

The Stryker EPS is 9.43.

What Is the Next Stryker Earnings Date?

Stryker will release its next earnings report on 04 Feb 2025.

From a Technical Analysis Perspective, Is SYK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.